|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | “En bloc ” caudate lobe and inferior vena cava resection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal and liver metastasis of colorectal cancer显示文摘There are diverse protocols to manage patients with recurrent disease after primary cytoreductive surgery(CRS) with hyperthermic intraperitoneal chemotherapy(HIPEC) for peritoneal carcinomatosis. We describe a case of metachronous liver metastasis after CRS and HIPEC for colorectal cancer, successfully treated with a selective metastectomy and partial graft of the inferior vena cava. A 35-year-old female presented with a large tumour in the cecum and consequent colonic stenosis. After an emergency right colectomy, the patient received adjuvant chemotherapy. One year later she was diagnosed with peritoneal carcinomatosis, and it was decided to carry out a CRS/HIPEC. After 2 years of total remission, an isolated metachronous liver metastasis was detected by magnetic resonance imaging surveillance. The patient underwent a third procedure including a caudate lobe and partial inferior vena cava resection with a prosthetic graft interposition, achieving an R0 situation. The postoperative course was uneventful and the patient was discharged on postoperative day 17 after the liver resection. At 18-mo follow-up after the liver resection the patient remained free of recurrence. In selected patients, the option of re-operation due to recurrent disease should be discussed. Even liver resection of a metachronous metastasis and an extended vascular resection are acceptable after CRS/HIPEC and can be considered as a potential treatment option to remove all macroscopic lesions. | Patricia Sánchez-Velázquez Nicolas Moosmann Ingolf T?pel Pompiliu Piso | 2016 | World Journal of Gastroenterology2016，22，46： | 3 |
| 2 | Multimodality treatment strategies have changed prognosis of peritoneal metastases显示文摘For a long time, treatment of peritoneal metastases(PM) was mostly palliative and thus, this status was link with 'terminal status/despair'. The current multimodal treatment strategy, consisting of cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC), has been strenuously achieved over time, but seems to be the best treatment option for PM patients. As we reviewed the literature data, we could emphasize some milestones and also, controversies in the history of proposed multimodal treatment and thus, outline the philosophy of this approach, which seems to be an unusual one indeed. Initially marked by nihilism and fear, but benefiting from a remarkable joint effort of human and material resources(multi-center and-institutional research), over a period of 30 years, CRS and HIPEC found their place in the treatment of PM. The next 4 years were dedicated to the refinement of the multimodal treatment, by launching research pathways. In selected patients, with requires training, it demonstrated a significant survival results(similar to the Hepatic Metastases treatment), with acceptable risks and costs. The main debates regarding CRS and HIPEC treatment were based on the oncologists' perspective and the small number of randomized clinical trials. It is important to statement the PM patient has the right to be informed of the existence of CRS and HIPEC, as a real treatment resource, the decision being made by multidisciplinary teams. | corneliu lungoci aurel ion mironiuc valentin muntean traian oniu hubert leebmann max mayr pompiliu piso | 2016 | World Journal of Gastrointestinal Oncology2016，8，1： | 2 |
| 3 | Proximal Versus Distal Gastric Carcinoma—What Are the Differences?显示文摘 | Pompiliu Piso MD Uwe Werner MD Hauke Lang MD Petrit Mirena MD Jürgen Klempnauer MD | 2000 | Annals of Surgical Oncology2000，，7： | 1 |
| 4 | Current Status and Future Directions in Gastric Cancer with Peritoneal Dissemination显示文摘 | Gabriel Glockzin Pompiliu Piso | 2012 | Surgical Oncology Clinics of North America2012，，4： | 1 |
| 5 | Differences in Attitude Toward Living and Postmortal Liver Donation in the United States, Germany, and Japan显示文摘 | Marc H. Dahlke Felix C. Popp Nadine Eggert Ludwig Hoy Hideaki Tanaka Katsunori Sasaki Pompiliu Piso Hans J. Schlitt | 2011 | Psychosomatics2011，，1： | 1 |
| 6 | Mitochondrial oxidative stress significantly influences atherogenic risk and cytokineinduced oxidant production显示文摘 | Harrison CM Pompilius M Pinkerton KE | 2011 | Environ Health Perspect2011，119，5： | 1 |
| 7 | Proximal versus distal gastric carcinoma-what are the differences?显示文摘 | Pompiliu P Uwe W Hauke L | 2000 | Ann Surg Oncol2000，7，7： | 1 |
| 8 | Treatment‐related morbidity and toxicity of CRS and oxaliplatin‐based HIPEC compared to a mitomycin and doxorubicin‐based HIPEC protocol in patients with peritoneal carcinomatosis: A matched‐pair analysis显示文摘 | Gabriel Glockzin Philipp von Breitenbuch Hans J. Schlitt Pompiliu Piso | 2012 | J. Surg. Oncol2012，，： | 1 |
| 9 | Intraabdominal septic complications following bowel resection for Crohn’s disease: detrimental influence on long-term outcome显示文摘 | Igors Iesalnieks Alexandra Kilger Heidi Gla? Rene Müller-Wille Frank Klebl Claudia Ott Ulrike Strauch Pompiliu Piso Hans J. Schlitt Ayman Agha | 2008 | International Journal of Colorectal Disease2008，，12： | 1 |
| 10 | Total mesorectal excision for middle and lower rectal cancer a single institution experience with 337 consecutive patients 显示文摘 | Pompiliu P Dahlke MH Mireua P | 2004 | J Surg Oncol2004，86，： | 1 |
| 11 | IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer显示文摘 | Gerrit Peters Silvia Gongoll Cord Langner Michael Mengel Pompiliu Piso Jürgen Klempnauer Josef Rüschoff Hans Kreipe Reinhard Wasielewski | 2003 | Virchows Archiv2003，，2： | 1 |
| 12 | Presence ofa peptide component of thymosin fraction-5 manifesting discrete cytostatic properties in HL-60 human promyelocytic leukemia cells显示文摘 | Spangelo B L Pompilius M Farrimond D D | 2005 | Int Immunopharm2005，5，78： | 1 |
| 13 | Intraabdominal septic complications following bowel resection for Crohn’s disease: detrimental influence on long-term outcome显示文摘 | Igors Iesalnieks Alexandra Kilger Heidi Gla? Rene Müller-Wille Frank Klebl Claudia Ott Ulrike Strauch Pompiliu Piso Hans J. Schlitt Ayman Agha | 2008 | International Journal of Colorectal Disease2008，，12： | 1 |
| 14 | Minimum alveolar anesthetic concentration of fluorinated alcohols in rats:relevance to theories of narcosis 显示文摘 | Edmond Ⅰ Egar Ⅱ Pompiliu L Micheal J | 1999 | Anesth Analg1999，88，4： | 1 |
| 15 | Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC–-Overview and Basics显示文摘 | Bj? rn L.D.M. Brü cher Pompiliu Piso Vic Verwaal Jesus Esquivel Marcello Derraco Yutaka Yonemura Santiago Gonzalez-Moreno J? rg Pelz Alfred K? nigsrainer Michael Str? hlein Edward A. Levine David Morris David Bartlett Olivier Glehen Alfredo Garofalo Avira | 2012 | Cancer Investigation2012，，3： | 1 |
| 16 | Total mesorectal excision for middle and lower rectal cancer a single institution experience with 337 consecutive patients 显示文摘 | Pompiliu P Dahlke MH Mireua P | 2004 | J Surg Oncol2004，86，： | 1 |
| 17 | Therapeutic options for peritoneal metastasis arising from colorectal cancer显示文摘Peritoneal metastasis is a common sign of advanced tumor stage, tumor progression or tumor recurrence in patients with colorectal cancer. Due to the improvement of systemic chemotherapy, the development of targeted therapy and the introduction of additive treatment options such as cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC), the therapeutic approach to peritoneal metastatic colorectal cancer(pm CRC) has changed over recent decades, and patient survival has improved. Moreover, in contrast to palliative systemic chemotherapy or best supportive care, the inclusion of CRS and HIPEC as inherent components of a multidisciplinary treatment regimen provides a therapeutic approach with curative intent. Although CRS and HIPEC are increasingly accepted as the standard of care for selected patients and have become part of numerous national and international guidelines, the individual role, optimal timing and ideal sequence of the different systemic, local and surgical treatment options remains a matter of debate. Ongoing and future randomized controlled clinical trials may help clarify the impact of the different components, allow for further improvement of patient selection and support the standar-dization of oncologic treatment regimens for pm CRC. The addition of further therapeutic options such as neo-adjuvant intraperitoneal chemotherapy or pressurized intraperitoneal aerosol chemotherapy, should be investig-ated to optimize therapeutic regimens and further improve the oncological outcome. | Gabriel Glockzin Hans J Schlitt Pompiliu Piso | 2016 | World Journal of Gastrointestinal Pharmacology and Therapeutics2016，7，3： | 1 |
| 18 | Total mesorectal excision for middle and lower rectal cancer a single institution experience with 337 consecutive patients显示文摘 | Pompiliu P Dahlke MH Mireua P | 2004 | J Surg Oncol2004，86，： | 1 |
| 19 | IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer显示文摘 | Gerrit Peters Silvia Gongoll Cord Langner Michael Mengel Pompiliu Piso Jürgen Klempnauer Josef Rüschoff Hans Kreipe Reinhard Wasielewski | 2003 | Virchows Archiv2003，，2： | 1 |
| 20 | Delayed Visceral Arterial Hemorrhage Following Whipple’s Procedure: Minimally Invasive Treatment with Covered Stents显示文摘 | Peter Heiss MD PhD Maike Bachthaler MD Okka Wilkea Hamer MD Pompiliu Piso MD Thomas Herold MD Hans Juergen Schlitt MD Stefan Feuerbach MD Niels Zorger MD | 2008 | Annals of Surgical Oncology2008，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员